Report Information More information from: https ://www.wis eguyreports .com/reports /495855
Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Review, H1 2016 Report / Search Code: WGR495855
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Review, H1 2016’, provides in depth analys is on Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted pipeline therapeutics . The report provides comprehens ive information on the Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR), targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in MelanocyteStimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - The report reviews Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to Melanocyte-Stimulating
Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Identify the us e of drugs for target identification and drug repurpos ing - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding MelanocyteStimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) Overview 7 Therapeutics Development 8 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) - Products under Development by Stage of Development 8 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) - Products under Development by Therapy Area 9 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) - Products under Development by Indication 10 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) - Products under Development by Companies 13 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) - Therapeutics As s es s ment 15 As s es s ment by Monotherapy/Combination Products 15 As s es s ment by Mechanis m of Action 16 As s es s ment by Route of Adminis tration 18 As s es s ment by Molecule Type 20 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) - Companies Involved in Therapeutics Development 22 Clinuvel Pharmaceuticals Limited 22 Mallinckrodt Plc 23 Palatin Technologies , Inc. 24 Retrophin Inc. 25 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R MC1R or MSHR) - Drug Profiles 26 afamelanotide - Drug Profile 26 Product Des cription 26 Mechanis m Of Action 26 R& D Progres s 26 ASP-3291 - Drug Profile 33 Product Des cription 33 Mechanis m Of Action 33 R& D Progres s 33 corticotropin - Drug Profile 34 Product Des cription 34 Mechanis m Of Action 34 R& D Progres s 34 cos yntropin - Drug Profile 36 Product Des cription 36 Mechanis m Of Action 36 R& D Progres s 36 CUV-9900 - Drug Profile 37 Product Des cription 37 Mechanis m Of Action 37
or or or or or
or or
or
or
R& D Progres s 37 PL-8176 - Drug Profile 38 Product Des cription 38 Mechanis m Of Action 38 R& D Progres s 38 PL-8177 - Drug Profile 39 Product Des cription 39 Mechanis m Of Action 39 R& D Progres s 39 SRX-1177 - Drug Profile 40 Product Des cription 40 Mechanis m Of Action 40 R& D Progres s 40 VLRX-001 - Drug Profile 41 Product Des cription 41 Mechanis m Of Action 41 R& D Progres s 41 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Dormant Projects 42 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Dis continued Products 43 Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Featured News & Pres s Releas es 44 Mar 24, 2016: NICE’s technical team invited s takeholders with an interes t in the treatment of erythropoietic protoporphyria 44 Feb 16, 2016: Clinuvel brief on European commercialis ation 44 Feb 12, 2016: SCENESSE receives US FDA orphan des ignation for cutaneous porphyrias 45 Dec 03, 2015: Pos itive preliminary res ults in Singaporean vitiligo s tudy 46 Dec 03, 2015: Update on North American vitiligo program for SCENESSE 47 Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Dis eas e Activity in Patients with Pers is tently Active Sys temic Lupus Erythematos us 48 Oct 13, 2015: Clinical Data on Mallinckrodt Pharmaceuticals ' H.P. Acthar Gel to be Unveiled at American College of Rheumatology 50 Oct 08, 2015: Clinical Data on Mallinckrodt Pharmaceuticals ' H.P. Acthar Gel to be Unveiled at American College of Rheumatology 50 Aug 27, 2015: FDA grants Clinuvel a Type C Meeting 51 Jul 02, 2015: New England Journal of Medicine publis hes pivotal Phas e III SCENESSE s tudies 52 Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Caus es Extreme Light Sens itivity 53 Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Caus es Extreme Light Sens itivity 54 Jun 05, 2015: SCENESSE Commercialis ation Update 55 May 05, 2015: Clinuvel announces innovative melanocortin for new indications 56 Apr 22, 2015: SolaranRx’s SRX-1177 Receives FDA Orphan Drug Des ignation as Malignant Melanoma Treatment 57 Appendix 59 Methodology 59 Coverage 59 Secondary Res earch 59 Primary Res earch 59 Expert Panel Validation 59 Contact Us 59 Dis claimer 60 Lis t of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 Number of Products under Development by Companies , H1 2016 13 Products under Development by Companies , H1 2016 14 As s es s ment by Monotherapy/Combination Products , H1 2016 15 Number of Products by Stage and Mechanis m of Action, H1 2016 17 Number of Products by Stage and Route of Adminis tration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Clinuvel Pharmaceuticals Limited, H1 2016 22 Pipeline by Mallinckrodt Plc, H1 2016 23 Pipeline by Palatin Technologies , Inc., H1 2016 24 Pipeline by Retrophin Inc., H1 2016 25 Dormant Projects , H1 2016 42 Dis continued Products , H1 2016 43 Lis t of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11
Comparative Analys is by Early Stage Products , H1 2016 12 As s es s ment by Monotherapy/Combination Products , H1 2016 15 Number of Products by Mechanis m of Actions , H1 2016 16 Number of Products by Stage and Mechanis m of Actions , H1 2016 16 Number of Products by Routes of Adminis tration, H1 2016 18 Number of Products by Stage and Routes of Adminis tration, H1 2016 18 Number of Products by Molecule Types , H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 20
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349